Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Rapport sur les actions

Capitalisation boursière : US$2.1b

Ligand Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 6/6

Ligand Pharmaceuticals possède un total de capitaux propres de $841.2M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $954.9M et de $113.7M. L'EBIT de Ligand Pharmaceuticals est $18.0M ce qui fait que son ratio de couverture des intérêts -3.2. Elle dispose de liquidités et de placements à court terme de $219.6M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts-3.2x
Argent liquideUS$219.64m
Fonds propresUS$841.18m
Total du passifUS$113.69m
Total des actifsUS$954.87m

Mises à jour récentes de la santé financière

Recent updates

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23
Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 30

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de LGND ( $309.4M ) dépassent ses passifs à court terme ( $24.8M ).

Passif à long terme: Les actifs à court terme de LGND ( $309.4M ) dépassent ses passifs à long terme ( $88.9M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: LGND est sans dette.

Réduire la dette: LGND n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 74.2%.

Couverture de la dette: LGND n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.

Couverture des intérêts: LGND n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.


Bilan


Découvrir des entreprises saines